Current status and future prospects of patient-derived induced pluripotent stem cells
Summary
Induced pluripotent stem cells (iPSCs) are produced from adult somatic cells through reprogramming, which behave like embryonic stem cells (ESCs) but avoiding the controversial ethical issues from destruction of embryos. Since the first discovery in 2006 of four factors that are essential for maintaining the basic characteristics of ESC, global researches have rapidly improved the techniques for generating iPSCs. In this paper, we review new insights into patient-specific iPSC and summarize selected "disease-in-a-dish" examples that model the genetic and epigenetic variations of human diseases. Although more researches need to be done, studies have increasingly focused on the potential utility of iPSCs. The usability of iPSC technology is changing the fields of disease modeling and precision treatment. Aside from its potential use in regenerative cellular therapy for degenerative diseases, iPSC offers a range of new opportunities for the study of genetic human disorders, particularly, rare diseases. We believe that this rapidly moving field promises many more developments that will benefit modern medicine. © 2021. Japan Human Cell Society.
| Authors | Wang Z, Zheng J, Pan R, Chen Y |
|---|---|
| Journal | Human cell |
| Publication Date | 2021 Nov;34(6):1601-1616 |
| PubMed | 34378170 |
| DOI | 10.1007/s13577-021-00592-2 |